Elironrasib
RMC-6291-101
Phase 2 small_molecule active
Quick answer
Elironrasib for Non-Small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at Revolution Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Revolution Medicines
- Indication
- Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active